UA77446C2 - Anthranilic acid amides and their use as inhibitors of vegf receptor tyrosine kinase, process for their preparation, pharmaceutical composition - Google Patents

Anthranilic acid amides and their use as inhibitors of vegf receptor tyrosine kinase, process for their preparation, pharmaceutical composition Download PDF

Info

Publication number
UA77446C2
UA77446C2 UA20040403226A UA20040403226A UA77446C2 UA 77446 C2 UA77446 C2 UA 77446C2 UA 20040403226 A UA20040403226 A UA 20040403226A UA 20040403226 A UA20040403226 A UA 20040403226A UA 77446 C2 UA77446 C2 UA 77446C2
Authority
UA
Ukraine
Prior art keywords
formula
compound
tautomer
anthranilic acid
oxide
Prior art date
Application number
UA20040403226A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UA77446C2 publication Critical patent/UA77446C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
UA20040403226A 2001-11-08 2002-07-11 Anthranilic acid amides and their use as inhibitors of vegf receptor tyrosine kinase, process for their preparation, pharmaceutical composition UA77446C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0126902.6A GB0126902D0 (en) 2001-11-08 2001-11-08 Organic compounds
PCT/EP2002/012444 WO2003040102A1 (en) 2001-11-08 2002-11-07 Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
UA77446C2 true UA77446C2 (en) 2006-12-15

Family

ID=9925448

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20040403226A UA77446C2 (en) 2001-11-08 2002-07-11 Anthranilic acid amides and their use as inhibitors of vegf receptor tyrosine kinase, process for their preparation, pharmaceutical composition

Country Status (28)

Country Link
US (2) US7091224B2 (es)
EP (1) EP1446382B1 (es)
JP (1) JP2005511602A (es)
KR (1) KR100602977B1 (es)
CN (1) CN1300113C (es)
AT (1) ATE496889T1 (es)
AU (1) AU2002351909B2 (es)
BR (1) BR0213970A (es)
CA (1) CA2463968C (es)
CO (1) CO5580823A2 (es)
DE (1) DE60239073D1 (es)
ES (1) ES2360283T3 (es)
GB (1) GB0126902D0 (es)
HR (1) HRP20040411A2 (es)
IL (1) IL161747A0 (es)
MX (1) MXPA04004391A (es)
NO (1) NO327231B1 (es)
NZ (1) NZ532590A (es)
PE (1) PE20030714A1 (es)
PL (1) PL368416A1 (es)
PT (1) PT1446382E (es)
RU (1) RU2318811C2 (es)
SA (1) SA02230412B1 (es)
TW (1) TWI260222B (es)
UA (1) UA77446C2 (es)
WO (1) WO2003040102A1 (es)
YU (1) YU36004A (es)
ZA (1) ZA200402940B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7307088B2 (en) * 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
GB0229022D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic Compounds
US7202260B2 (en) 2003-06-13 2007-04-10 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
DE10327719A1 (de) * 2003-06-13 2005-01-20 Schering Ag VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone
US7129252B2 (en) * 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
EP1568368A1 (en) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1655295A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
CA2588633A1 (en) 2004-12-07 2006-06-15 Toyama Chemical Co., Ltd. Novel anthranilic acid derivative or salt thereof
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CN101265274B (zh) * 2007-02-16 2013-09-04 中国医学科学院药物研究所 嘧啶噻唑胺衍生物、及其制法和药物组合物与用途
CA2734551A1 (en) 2008-08-27 2010-03-04 Leo Pharma A/S Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
GB201322538D0 (en) 2013-06-21 2014-02-05 Immusmol Sas Method for detecting small molecules in a sample
CN107954893A (zh) * 2017-11-28 2018-04-24 兰州纬寰生物科技有限公司 邻氨基苯甲酰胺衍生物及制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
IL161747A0 (en) 2005-11-20
KR100602977B1 (ko) 2006-07-20
JP2005511602A (ja) 2005-04-28
ZA200402940B (en) 2005-02-10
NO20042187L (no) 2004-05-26
PL368416A1 (en) 2005-03-21
NO327231B1 (no) 2009-05-18
AU2002351909B2 (en) 2007-04-26
CN1585750A (zh) 2005-02-23
SA02230412B1 (ar) 2007-07-31
US7482369B2 (en) 2009-01-27
TW200300087A (en) 2003-05-16
US20050096356A1 (en) 2005-05-05
NZ532590A (en) 2005-12-23
HRP20040411A2 (en) 2005-04-30
BR0213970A (pt) 2004-08-31
CA2463968A1 (en) 2003-05-15
RU2318811C2 (ru) 2008-03-10
US20060178409A1 (en) 2006-08-10
PE20030714A1 (es) 2003-10-13
MXPA04004391A (es) 2005-12-12
GB0126902D0 (en) 2002-01-02
CN1300113C (zh) 2007-02-14
ATE496889T1 (de) 2011-02-15
WO2003040102A1 (en) 2003-05-15
CA2463968C (en) 2011-02-22
ES2360283T3 (es) 2011-06-02
RU2004117543A (ru) 2006-01-10
YU36004A (sh) 2006-08-17
KR20050044382A (ko) 2005-05-12
CO5580823A2 (es) 2005-11-30
DE60239073D1 (de) 2011-03-10
PT1446382E (pt) 2011-05-03
EP1446382B1 (en) 2011-01-26
US7091224B2 (en) 2006-08-15
EP1446382A1 (en) 2004-08-18
TWI260222B (en) 2006-08-21

Similar Documents

Publication Publication Date Title
UA77446C2 (en) Anthranilic acid amides and their use as inhibitors of vegf receptor tyrosine kinase, process for their preparation, pharmaceutical composition
KR102120883B1 (ko) 인간 히스톤 메틸트랜스퍼라제 ezh2 억제제의 염 형태
RU2658919C2 (ru) Замещенные бензольные соединения
CN110573500B (zh) N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用
ES2878973T3 (es) Derivado de fenilo de imidazopiridinamina y uso del mismo
AU2017366901A1 (en) Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
EP1562938A1 (en) Heteroaryl-pyrimidine derivatives as jak inhibitors
AU2002351909A1 (en) Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors
WO2018214866A9 (zh) 一种氮杂芳基衍生物、其制备方法和在药学上的应用
CN118055933A (zh) 选择性parp1抑制剂及其应用
WO2018137639A1 (zh) 一种组蛋白甲基转移酶ezh2抑制剂、其制备方法及其医药用途
WO2016140501A1 (en) Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors
RU2315756C2 (ru) Амиды антраниловой кислоты и их применение в фармацевтике
EP1572686B1 (en) Anthranilic acid amide derivatives and their pharmaceutical use
CN115197221B (zh) 二氢吡唑并嘧啶酮类大环衍生物及其用途
KR102344185B1 (ko) 신규한 Pim 키나아제 억제제 및 이의 용도
KR20230107566A (ko) 세로토닌 1b 수용체 조절제로서 효력있고 선택적인 화합물
CN116102545A (zh) 一种二芳基脲类PI3K/mTOR/HDAC多靶点抑制剂及其药物组合物和应用
UA77448C2 (en) Anthranilic acid amide derivatives and their use in pharmaceutics
TW202312995A (zh) 氮雜芳基化合物、其製備方法及應用
AU2013208847A1 (en) Novel heteroarylamide derivatives having antiandrogenic properties